PCM
SCMP

Palisade Capital Management’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Palisade Capital Management’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-29,500
Closed -$348K – 462
2017
Q3 		$348K Sell
29,500
-500
-2% -$5.61K 0.01% 384
2017
Q2 		$315K Hold
30,000
– – 0.01% 402
2017
Q1 		$330K Buy
30,000
+500
+2% +$5.8K 0.01% 392
2016
Q4 		$400K Buy
+29,500
New +$412K 0.02% 417

Other funds holding SCMP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Palisade Capital Management's SCMP Position: Q4 2017 in Review

Palisade Capital Management sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q4 2017, closing a stake of 29,500 shares — an estimated $348K sold.

Palisade Capital Management first reported a position in SCMP in Q4 2016 and held it in 4 quarters. The position peaked at $400K in Q4 2016. 188 funds tracked by Wall St. Rank hold SCMP as of Q4 2017.

  • Palisade Capital Management reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Palisade Capital Management sold 29,500 Sucampo Pharmaceuticals, Inc. shares in Q4 2017, an estimated $348K.
  • Palisade Capital Management first reported a position in Sucampo Pharmaceuticals, Inc. in Q4 2016 and held it in 4 quarters.
  • Palisade Capital Management's Sucampo Pharmaceuticals, Inc. position peaked at $400K in Q4 2016.
  • 188 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q4 2017.

Based on Palisade Capital Management's 13F filing for Q4 2017, filed 9 Feb 2018.